Targeting immune cells is important; indeed, the combination of a CD40 agonist and a PD-1 antagonist MAb exerts anti-tumor effects, which are manifested through tumor infiltration by IFNγ-, Granzyme B-, and TNFα-secreting effector T cells [79]. The gene discussed is CD40; the disease is neoplasm.